Clinical Trials on Adenocarcinoma Breast

Total 22932 results

Gustave Roussy, Cancer Campus, Grand Paris

Withdrawn

Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors (MATILDA)

Metastatic Colorectal Cancer | Triple Negative Breast Cancer | Esophageal Adenocarcinoma | Prostate Adenocarcinoma | Stomach Adenocarcinoma
H. Lee Moffitt Cancer Center and Research Institute

Terminated

Preoperative Stereotactic Ablative Body Radiotherapy (SABR) for Early-Stage Breast Cancer

Breast Cancer | Breast Cancer Female | Breast Adenocarcinoma

United States
M.D. Anderson Cancer Center

Withdrawn

Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Breast Carcinoma | Hormone Receptor Positive Breast Adenocarcinoma | Metastatic HER2 Negative Breast Adenocarcinoma

United States
Apollo Therapeutics Ltd

Not yet recruiting

A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors

Colorectal Cancer | Pancreatic Adenocarcinoma | Ovarian Cancer | Prostate Cancer | Gastric Adenocarcinoma | Cholangiocarcinoma | Triple Negative Breast Cancer | Endometrial Adenocarcinoma | Appendiceal Adenocarcinoma
Filipa Lynce, MD
AstraZeneca; Daiichi Sankyo, Inc.

Recruiting

TRUDI: TDXD+Durva in HER2+/Low IBC (TRUDI)

Breast Cancer | HER2-positive Breast Cancer | Invasive Breast Cancer | Inflammatory Breast Cancer Stage III | HER2 Low Breast Adenocarcinoma

United States
BioInvent International AB

Active, not recruiting

BI-1607 in Combination With Trastuzumab in Subjects With HER2-positive Advanced Solid Tumors (CONTRAST)

HER2-positive Breast Cancer | HER2-positive Gastric Cancer | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | HER2-positive Metastatic Breast Cancer

Spain, United Kingdom, Germany
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Unresectable Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Metastatic Breast Adenocarcinoma | Metastatic HER2-Positive Breast Carcinoma | Recurrent Breast Adenocarcinoma | Recurrent HER2-Positive Breast Carcinoma | Unresectable HER2-Positive Breast Carcinoma

United States, Canada
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Study of the Safety of MRI Scans in People Who Have Breast Tissue Expanders After Mastectomy

Breast Cancer | Breast Neoplasms | Breast Adenocarcinoma

United States
National Cancer Institute (NCI)

Completed

Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer

Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Recurrent Breast Carcinoma | Metastatic Triple-Negative Breast Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Recurrent... and other conditions

United States
Boehringer Ingelheim

Not yet recruiting

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib in Combination With Trastuzumab Deruxtecan or With Trastuzumab Emtansine and to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Metastatic Breast Cancer | Esophageal Adenocarcinoma | Metastatic Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma
Hellenic Cooperative Oncology Group

Completed

Adjuvant Chemotherapy With Epirubicin, CMF, and Weekly Docetaxel or Weekly Paclitaxel in Patients With Resected High-risk Breast Cancer

Breast Cancer | Adenocarcinoma of Breast
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer

Breast Adenocarcinoma | HER2-Positive Breast Carcinoma

United States
Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company
AstraZeneca

Completed

DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein

Neoplasm, Breast | Adenocarcinoma, Gastric

Taiwan
Memorial Sloan Kettering Cancer Center
Pfizer; Amgen

Completed

Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: Feasibility

Breast Cancer | Adenocarcinoma of the Breast

United States
Richard Zellars

Active, not recruiting

Partial Irradiation and Sequential vs. Concurrent Chemo Early Breast Cancer

Breast Cancer | Adenocarcinoma of the Breast

United States
Immutep S.A.S.

Completed

IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma

Adenocarcinoma Breast Stage IV

Netherlands, United Kingdom, France, Belgium, Germany, Hungary, Poland
Memorial Sloan Kettering Cancer Center

Completed

Pre-Operative, Single-Dose Ipilimumab and/or Cryoablation in Early Stage/Resectable Breast Cancer

Breast Cancer | Invasive Adenocarcinoma of the Breast

United States
Swiss Group for Clinical Cancer Research

Terminated

CR1447 in Endocrine Responsive-HER2neg and TN-ARpos Breast Cancer

Breast Cancer | Metastatic Breast Adenocarcinoma

Switzerland
Virginia Commonwealth University

Active, not recruiting

Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer

Breast Cancer | Invasive Breast Carcinoma | Lobular Breast Carcinoma In Situ | Breast Adenocarcinoma | Node-positive Breast Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

Ovarian Endometrioid Adenocarcinoma | Fallopian Tube Carcinoma | Triple-Negative Breast Carcinoma | Ovarian Serous Adenocarcinoma | Primary Peritoneal Serous Adenocarcinoma | Ovarian High Grade Serous Adenocarcinoma | Ovarian Serous Surface Papillary Adenocarcinoma

United States
General Oncology, Inc.
Myriad Genetics, Inc.

Recruiting

SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells

Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer Stage IV | Breast Cancer Stage IV | BRCA1 Mutation | BRCA2 Mutation | Pancreatic Acinar Cell Carcinoma | Metastatic Pancreatic Cancer | Breast Cancer Metastatic | HER2-negative Breast Cancer | Metastatic Pancreatic Ductal Adenocarcinoma and other conditions

United States
Accelerated Community Oncology Research Network
Amgen

Terminated

Panitumumab, Paclitaxel, Carboplatin and 5FU in the Treatment of Potentially Resectable Gastroesophageal Adenocarcinoma

Gastroesophageal Adenocarcinoma | Adenocarcinomas of the Gastroesophageal Junction | Adenocarcinoma of the Distal Esophagus | Adenocarcinoma of the Proximal Stomach

United States
University of Washington
National Cancer Institute (NCI)

Recruiting

Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Breast Adenocarcinoma | Invasive Breast Carcinoma of No Special Type

United States
Eisai Inc.

Completed

Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer

Breast Cancer | Breast Neoplasms | Cancer, Breast | Breast Cancer Female | Estrogen Receptor Positive Tumor | Breast Adenocarcinoma | ER Positive | Estrogen-receptor Positive Breast Cancer

France, United Kingdom, United States
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

Effects of Ribociclib and Palbociclib on Tumor and Blood Characteristics in Patients With Metastatic Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditions
Sidney Kimmel Cancer Center at Thomas Jefferson...

Active, not recruiting

Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer

Breast Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Uterine Corpus Cancer | Uterine Corpus Carcinosarcoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Aventis Pharmaceuticals

Terminated

Pharmacogenomic Study of Docetaxel and Cisplatin, Followed by Docetaxel, Cisplatin and Irradiation.

Esophageal Adenocarcinomas | Adenocarcinomas of the Gastroesophageal Junction

United States
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group; Cancer and Leukemia Group B; North Central...

Active, not recruiting

Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

Breast Adenocarcinoma

United States, Peru, South Africa
Mayo Clinic

Recruiting

Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative Breast Cancer

Invasive Breast Carcinoma | Breast Adenocarcinoma | Resectable Breast Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer

Invasive Breast Carcinoma | HER2/Neu Negative | Breast Adenocarcinoma | Deleterious BRCA1 Gene Mutation | Deleterious BRCA2 Gene Mutation

United States
National Cancer Institute (NCI)

Active, not recruiting

Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer

Malignant Solid Neoplasm | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Invasive Breast Carcinoma | Breast Adenocarcinoma

United States
Indiana University

Terminated

Lymph Fluid and Blood Collection for Identification of Novel Biomarkers

Adenocarcinoma of the Breast

United States
Rambam Health Care Campus

Unknown

Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas

Lung Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Breast Adenocarcinoma
M.D. Anderson Cancer Center

Active, not recruiting

Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer

Invasive Breast Carcinoma | Triple-Negative Breast Carcinoma | Breast Adenocarcinoma

United States
OHSU Knight Cancer Institute
Eli Lilly and Company; GlaxoSmithKline; Oregon Health and Science University

Active, not recruiting

Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Prognostic... and other conditions

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Suspended

Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer

Invasive Breast Carcinoma | HER2/Neu Negative | Stage IV Breast Cancer AJCC v6 and v7 | Stage IIIC Breast Cancer AJCC v7 | Breast Adenocarcinoma

United States
UMC Utrecht
Center for Translational Molecular Medicine; Dutch Cancer Society; Vrienden UMC...

Recruiting

Image-guided Targeted Doxorubicin Delivery With Hyperthermia to Optimize Loco-regional Control in Breast Cancer (i-GO)

Breast Cancer | Breast Neoplasms | Metastatic Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Invasive Ductal Breast Cancer | Invasive Ductal Carcinoma of Female Breast | Adenocarcinoma Breast

Netherlands
National Cancer Institute (NCI)

Withdrawn

Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | Ovarian Serous Adenocarcinoma | Primary Peritoneal... and other conditions
National University Hospital, Singapore

Recruiting

Trial of Lenvatinib Plus PembrolizumAb in Recurrent Gynecological Clear Cell Adenocarcinomas (LARA)

Adenocarcinomas | Recurrent Gynecological

Singapore
Hellenic Cooperative Oncology Group

Active, not recruiting

Investigation of Gene Mutations in Patients With Triple-negative and Patients With HER2+ Breast Cancer Adenocarcinoma

Breast Cancer

Greece
Swiss Group for Clinical Cancer Research

Terminated

Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer

Adenocarcinoma | Breast Cancer

Switzerland
Bristol-Myers Squibb

Completed

Study of MDX-010 in Stage IV Breast Cancer

Adenocarcinoma | Breast Cancer

United States
G1 Therapeutics, Inc.

Active, not recruiting

G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

Breast Cancer | Breast Neoplasm | Carcinoma, Ductal, Breast

United Kingdom, Bulgaria, Georgia, Moldova, Republic of
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

Stage IIIA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | Breast Adenocarcinoma

United States, Canada
Prescient Therapeutics, Ltd.
National Cancer Institute (NCI)

Terminated

PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Positive | HER2/Neu Negative | Breast Adenocarcinoma

United States
University of Lausanne Hospitals

Completed

Prospective Evaluation of the Role of MRI in the Perioperative Management of Pancreas Adenocarcinomas

Pancreas Adenocarcinomas

Switzerland
Medical College of Wisconsin

Active, not recruiting

Multi-Institutional Transgender & Gender-Diverse Breast Cancer Study

Breast Cancer | Breast Neoplasms | Breast Cancer Stage IV | Breast Adenocarcinoma | Breast Cancer Stage | Breast Cancer Invasive | Breast Cancer in Situ

United States
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group; Canadian Cancer Trials Group; Southwest Oncology... and other collaborators

Completed

Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer

HER2 Positive Breast Carcinoma | Stage IA Breast Cancer AJCC v7 | Stage IB Breast Cancer AJCC v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIA Breast Cancer AJCC v7 | Breast Adenocarcinoma

United States, Canada, Peru, South Africa
MedImmune LLC

Completed

A Study to Evaluate the Safety and Tolerability of MEDI-565 in Adults With Gastrointestinal Adenocarcinomas

Gastrointestinal Adenocarcinomas

United States
G1 Therapeutics, Inc.

Completed

G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer

Breast Cancer | Advanced Breast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Stage IV Breast Cancer | Carcinoma, Ductal, Breast | Breast Cancer Female

United States, Belgium, Bulgaria, Georgia, Netherlands, Moldova, Republic of, Ukraine

Clinical Trials on Adenocarcinoma Breast

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Greece

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations